Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18-methoxycoronaridine
- Development stage
- Phase 2
- Lead developer
- Albany Medical College
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
**18-methoxycoronaridine** is a synthetic congener of the iboga alkaloid coronaridine, developed as a potential treatment for substance use disorders and other conditions. It was invented in 1996 by researchers at Albany Medical College and the University of Vermont. Mechanistically, it acts primarily as an antagonist at neuronal nicotinic acetylcholine receptors containing α3β4 subunits, modulating reward pathways implicated in addiction. In animal studies, it reduces self-administration of morphine, cocaine, methamphetamine, nicotine, ethanol, and sucrose without the neurotoxic or tremorigenic side effects associated with ibogaine. It also produces anorectic effects in obese rats. Clinical development has included trials for opioid withdrawal and cutaneous leishmaniasis[1][2][3][4][5].
- Brand names
- zolunicant
- Other names
- 18-methoxycoronaridineZolunicant [INN](-)-18-MethoxycoronaridineIbogamine-18-carboxylic acid, 21-methoxy-, methyl ester(+/-)-18-Methoxycoronaridine
02
Targets
Muscle-type nicotinic acetylcholine receptor
Beyond the preview
Go deeper on 18-methoxycoronaridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18-methoxycoronaridine.